155 related articles for article (PubMed ID: 38686383)
1. Development and validation of an MRI-Based nomogram to predict the effectiveness of immunotherapy for brain metastasis in patients with non-small cell lung cancer.
Xu J; Wang P; Li Y; Shi X; Yin T; Yu J; Teng F
Front Immunol; 2024; 15():1373330. PubMed ID: 38686383
[TBL] [Abstract][Full Text] [Related]
2. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
3. Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancer.
Shi X; Wang P; Li Y; Xu J; Yin T; Teng F
Thorac Cancer; 2024 Mar; 15(9):738-748. PubMed ID: 38376861
[TBL] [Abstract][Full Text] [Related]
4. CT-based radiomics for predicting brain metastases as the first failure in patients with curatively resected locally advanced non-small cell lung cancer.
Sun F; Chen Y; Chen X; Sun X; Xing L
Eur J Radiol; 2021 Jan; 134():109411. PubMed ID: 33246270
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study.
Wu S; Zhan W; Liu L; Xie D; Yao L; Yao H; Liao G; Huang L; Zhou Y; You P; Huang Z; Li Q; Xu B; Wang S; Wang G; Zhang DK; Qiao G; Chan LW; Lanuti M; Zhou H
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37865396
[TBL] [Abstract][Full Text] [Related]
6. Survival time following resection of intracranial metastases from NSCLC-development and validation of a novel nomogram.
Ji X; Zhuang Y; Yin X; Zhan Q; Zhou X; Liang X
BMC Cancer; 2017 Nov; 17(1):774. PubMed ID: 29157203
[TBL] [Abstract][Full Text] [Related]
7. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.
Vaidya P; Bera K; Patil PD; Gupta A; Jain P; Alilou M; Khorrami M; Velcheti V; Madabhushi A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051342
[TBL] [Abstract][Full Text] [Related]
8. MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer.
Zhao S; Hou D; Zheng X; Song W; Liu X; Wang S; Zhou L; Tao X; Lv L; Sun Q; Jin Y; Ding L; Mao L; Wu N
Transl Lung Cancer Res; 2021 Jan; 10(1):368-380. PubMed ID: 33569319
[TBL] [Abstract][Full Text] [Related]
9. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer.
Tunali I; Tan Y; Gray JE; Katsoulakis E; Eschrich SA; Saller J; Aerts HJWL; Boyle T; Qi J; Guvenis A; Gillies RJ; Schabath MB
JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409252
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral and peritumoral radiomics nomograms for the preoperative prediction of lymphovascular invasion and overall survival in non-small cell lung cancer.
Chen Q; Shao J; Xue T; Peng H; Li M; Duan S; Feng F
Eur Radiol; 2023 Feb; 33(2):947-958. PubMed ID: 36064979
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition.
Li Y; Wang P; Xu J; Shi X; Yin T; Teng F
Oncoimmunology; 2024; 13(1):2312628. PubMed ID: 38343749
[TBL] [Abstract][Full Text] [Related]
14. Development of a radiomics nomogram based on the 2D and 3D CT features to predict the survival of non-small cell lung cancer patients.
Yang L; Yang J; Zhou X; Huang L; Zhao W; Wang T; Zhuang J; Tian J
Eur Radiol; 2019 May; 29(5):2196-2206. PubMed ID: 30523451
[TBL] [Abstract][Full Text] [Related]
15. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics-Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer.
Yu Y; Tan Y; Xie C; Hu Q; Ouyang J; Chen Y; Gu Y; Li A; Lu N; He Z; Yang Y; Chen K; Ma J; Li C; Ma M; Li X; Zhang R; Zhong H; Ou Q; Zhang Y; He Y; Li G; Wu Z; Su F; Song E; Yao H
JAMA Netw Open; 2020 Dec; 3(12):e2028086. PubMed ID: 33289845
[TBL] [Abstract][Full Text] [Related]
17. Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer.
Wang L; Dong T; Xin B; Xu C; Guo M; Zhang H; Feng D; Wang X; Yu J
Eur Radiol; 2019 Jun; 29(6):2958-2967. PubMed ID: 30643940
[TBL] [Abstract][Full Text] [Related]
18. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Qu J; Zhang T; Zhang X; Zhang W; Li Y; Gong Q; Yao L; Lui S
Clin Radiol; 2024 Apr; 79(4):e582-e591. PubMed ID: 38310058
[TBL] [Abstract][Full Text] [Related]
19. Improving survival prediction of high-grade glioma via machine learning techniques based on MRI radiomic, genetic and clinical risk factors.
Tan Y; Mu W; Wang XC; Yang GQ; Gillies RJ; Zhang H
Eur J Radiol; 2019 Nov; 120():108609. PubMed ID: 31606714
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
